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Abstract
Background: Retroperitoneal lymph node dissection has been advocated for the management of post-
chemotherapy (PC-RPLND) residual masses of non-seminomatous germ cell tumors of the testis (NSGCT). There
remains some debate as to the clinical benefit and associated morbidity. Our objective was to report our
experience with PC-RPLND in NSGCT.
Methods: We have reviewed the clinical, pathologic and surgical parameters associated with PC-RPLND in a single
institution. Between 1994 and 2008, three surgeons operated 73 patients with residual masses after cisplatin-based
chemotherapy for a metastatic testicular cancer. Patients needed to have normal postchemotherapy serum tumor
markers, no prior surgical attempts to resect retroperitoneal masses and resectable retroperitoneal tumor mass at
surgery to be included in this analysis
Results: Mean age was 30.4 years old. Fifty-three percent had mixed germ cell tumors. The mean size of
retroperitoneal metastasis was 6.3 and 4.0 cm, before and post-chemotherapy, respectively. In 56% of patients, the
surgeon was able to perform a nerve sparing procedure. The overall complication rate was 27.4% and no patient
died due to surgical complications. The pathologic review showed presence of fibrosis/necrosis, teratoma and
viable tumor (non-teratoma) in 27 (37.0%), 30 (41.1%) and 16 (21.9%) patients, respectively. The subgroups
presenting fibrosis and large tumors were more likely to have a surgical complication and had less nerve sparing
procedures.
Conclusion: PC-RPLND is a relatively safe procedure. The presence of fibrosis and large residual masses are
associated with surgical complications and non-nerve-sparing procedure.
Background
In accordance with the last report of The Public Health
Agency of Canada (PHAC), the incidence of testicular
cancer in Canada is rising and is the most common can-
cer in young men. The two main histologic subgroups
occur with similar frequencies: 54% are seminoma and
41% non-seminoma germ cell tumors; 5% are other
types[1].
Testicular cancer has become the model for a curable
neoplasm. In treatment of nonseminomatous germ cell
testicular tumors (NSGCTT), there have been great
improvements in the last 25 years. Cure rates for clinical
stage I and low-volume stage II testis tumor patients
approach 100%; selecting the best initial modality of
treatment and integration of surgery and chemotherapy
is critical to optimizing cure and minimizing morbidity
[2,3]. Furthermore, stage IIb and III metastatic NSGCT
have very high cure rates owing to improvements in
multi-drug chemotherapy protocols based on cisplatin.
Nearly 80% of the patients presenting with retroperito-
neal residual masses as the only site of metastasis after
cisplatin-based chemotherapy can be cured by post-
chemotherapy retroperitoneal lymphadenectomy (PC-
RPLND). Of the patients requiring resection of residual
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will have either necrosis or teratoma in their resected
specimens. This number decreases to 50% in patients
undergoing resection after salvage chemotherapy[3,4]
Currently, RPLND of residual masses after cisplatin-
based chemotherapy is a widely accepted procedure.
There are some efforts to limit the extent of surgical
resection boundaries to reduce complications[4]. In 40-
50% of patients undergoing postchemotherapy resection
of residual disease and bilateral RPLND, the histological
diagnosis of the surgical specimen will be necrosis[5].
Thus, in a substantial proportion of patients, adjunctive
surgery offers no additional therapeutic benefit. In an
effort to select the patients who do not need surgery,
some investigators have advocated the use of various
radiographic and histological parameters. However
despite these efforts, the risk of omitting surgery in a
patient who harbors viable cancer or teratoma appears
to be 20%[6,7].
Since it appears difficult to predict which patients
require PC-RPLND for residual masses that harbor
viable cancer or teratoma, there remains significant con-
cern regarding surgical complications. We report our
experience with PC-RPLND for residual disease and
examine the complications as well as histologic and clin-
ical outcomes.
Methods
Between 1994 and 2008, three surgeons performed 81
RPLND for a residual mass(es) after cisplatin-based che-
motherapy for clinical stages II or III testicular NSGCT.
All patients were operated at the Montreal General Hos-
pital (McGill University Health Center). The inclusion
criteria were: nonseminomatous tumors, normal post-
chemotherapy serum alpha-fetoprotein and human
chorionic gonadotrophin levels and no prior surgical
attempts to resect retroperitoneal tumours. Exclusion
criteria were: incomplete data, inadequate follow-up and
surgical treatment performed in another hospital.
Patients who underwent primary RPLND or radiother-
apy were also excluded. PC-RPLND consisted of a full
bilateral template limited by the renal vessels, the
ureters and the bifurcation of common iliac vessels.
Complications were reported according to the relatively
new classification of surgical complications proposed by
Clavien[8], using a scale from I to V. Statistical analysis
was done using SPSS version 11.1 for descriptive analy-
sis, comparing means of subgroups (independent t-tests)
and comparing groups to surgical complications and
presence of viable cancer (Chi-square test, Fisher’s exact
test). Independent predictors of complications and/or
presence of viable disease were analyzed (age, laterality,
comorbidities, initial histology, tumor markers, risk,
initial tumor size, initial and residual mass size, surgical
technique, operative time) The disease free survival rate
(calculated from the time of retroperitoneal surgery
until the first clinical evidence of recurrence) was calcu-
lated using a Kaplan-Meier curve and comparisons by
Log Rank test.
Results
Of the 81 cases, 73 fulfilled the inclusion criteria. The
mean age was 30.6 years ranging from 16 to 58. Only
6 patients (8.2%) had some preoperative comorbidity
including sarcoidosis (1), hypertension (1), chronic renal
failure (1), epilepsy (1), atrial fibrillation (1) and duode-
nal ulcer (1). The patient with chronic renal failure
underwent a kidney transplantation before the diagnosis
of testis cancer. Chryptorchidism was present in 8 (11%)
patients, with two being bilateral.
The primary tumor was located on the right side in 34
(46.6%) cases. The most prevalent histology of the pri-
mary tumor was mixed germ cell tumor, present in 50
cases (60.8%). Thirty-one patients (42.5%) presented
some component of teratoma. Two cases showed
burned-out tumours. The testis tumor characteristics
are summarized in Table 1.
The mean size of retroperitoneal metastasis was 6.3
cm before chemotherapy and 4.0 cm after systemic
treatment (p < 0.001). The most common sites of retro-
peritoneal metastasis was paraortic (Figure 1), paracaval
and interaortocaval in 33 (45.2%), 19 (26.0%) and 14
(19.2%) patients, respectively.
All patients were submitted to cisplatin-based che-
motherapy regimens. The most common was BEP (bleo-
mycin, etoposide and cisplatin) for 2 to 4 cycles in
Table 1 Clinical and pathological features of testis
tumors
Characteristic n (%)
Size (mean, cm) 3.5 (±2.0)
Laterality Left 34 (46.6)
Right 37 (50.7)
Clinical Stage IIA 9 (12.3)
IIB 28 (38.4)
IIC 22 (30.1)
III 14 (19.2)
Histology MGCT 50 (68.5)
EC 13 (17.8)
Teratoma 7 (9.6)
Others 3 (4.2)
Tumor risk Good 56 (76.7)
Intermediate 10 (13.7)
Poor 7 (9.6)
LV invasion 24 (32.9)
CIS 9 (12.3)
MGCT = mixed germ cell tumor, EC = Embryonal carcinoma, LV =
lymphvascular, Ca = carcinoma in situ
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Page 2 of 657 patients (78.1%). EP (etoposide and cisplatin), VIP
(vinblastin, ifosfamide and cisplatin) or a combination of
regimens were used in 3 (4.1%), 4 (5.5%) and 9 (12.3%),
respectively. Additional treatments to normalize the
markers were necessary in 7 cases (9.6%) and two
patients were submitted to bone marrow transplantation
to rescue high dose chemotherapy treatment. The char-
acteristics of post-chemotherapy retroperitoneal disease
are described in Table 2.
The surgical approach was abdominal in 70 (95.9%)
cases and thoracoabdominal in 3 cases. A complete
bilateral retroperitoneal dissection was performed in 67
(92.0%) patients. In six (8.0%) patients, right or left uni-
lateral modified template was performed. The surgeon
classified the resection as complete or incomplete based
on surgical findings. In 8 (10.9%) cases the surgeon’s
opinion was that an incomplete resection was done. Of
these cases, in only 1 (1.4%) viable tumor was identified
and the follow-up did not show local disease recurrence.
An organ resection was necessary in 18 (24.6%) patients,
most often a vascular resection (8 cases) or nephrect-
omy (5 cases). Vascular resections were composed of
aorta replacement in 2 cases, vena cava replacement in
2 cases, iliac artery partial resection in 2 cases, aorta
and superior mesenteric artery in 1 case and simulta-
neous aorta and vena cava replacement in 1 case. The
characteristics of surgical procedures are demonstrated
in Table 3.
The most common surgical complications observed
were lymphatic leak or lymphocele (10.9%), requiring
treatment with percutaneous drainage in 4.1%. Surgical
complications are reported in Table 4, according to the
Clavien classification.
The histology from RPLND specimens demonstrated
fibrosis or necrosis in 27 (37.0%), teratoma in 30
(41.1%) and viable carcinoma in 16 (21.9%) cases.
Among these 16 cases which presented viable cancer, 4
(25%) had metastasis beyond retroperitoneal, 7 (43.8%)
showed retroperitoneal masses larger than 5 cm, 8
(50%) presented initial clinical stage IIC or III and 6
(37.5%) required re-induction chemotherapy. However,
only 2 (2.7%) of these 16 patients presented high risk
disease according to IGCTC at initial assessment. After
PC-RPLND, 7 out of 16 patients with viable cancer
received additional chemotherapy (adjuvant).
Figure 1 Large post-chemotherapy residual paraortic mass
(teratoma).
Table 2 Clinical characteristics of retroperitoneal
metastasis
Characteristic n (%)
Size Before CT 6.3 (±3.9) p < 0.001
After CT 4.0 (±2.6)
Main site Paraortic 33 (45.2)
Paracaval 19 (26.0)
Interaortocaval 14 (19.2)
Precaval 3 (4.1)
Retrocural 3 (4.1)
Iliac 1 (1.4)
CT = chemotherapy treatment
Table 3 Retroperitoneal Lymph Node Dissection
Characteristic n (%)
Template Bilateral 67 (91.8)
Extended 4 (5.5)
Modified Right 1 (1.4)
Modified Left 1 (1.4)
Nerve sparing Bilateral 33 (45.2)
Only left 4 (5.5)
Only right 5 (6.8)
No 31 (42.5)
Ureterolysis 7 (9.58)
Operative time (min) 366 (±94)
EBL (ml) 765 (±1494)
Packed RBC transfusion (units) 0.96 (±2.3)
Frozen section 38 (52)
Hospital stay (days) 8.5 (±6.4)
NGT (days) 2.3 (±1.7)
Clear liquids (days) 2.9 (±2.5)
EBL = estimated blood loss, RBC = red blood cells, NGT = nasogastric tube
Table 4 Surgical Complications (Clavien Classification)
No complications 45 (61.64%)
I (superficial wound infection, fever) 9 (5.6%)
II (ileus, DVT) 5 (7.0%)
IIIa (symptomatic lymphocele, ureteral leak) 6 (8.4%)
IIIb (laparotomy, incisional hernia) 5 (7.0%)
IVa (acute renal failure, respiratory distress) 2 (2.8%)
IVb (multiple organ failure) 1 (1.4%)
V (death) 0 (0.0%)
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observed a correlation between the presence of fibrosis
with non-nerve sparing surgeries and surgical complica-
tions (p < 0.05) (Figure 2a/2b). In other words, in the pre-
s e n c eo ff i b r o s i s ,i tw a sm o r el i k e l yt oh a v eas u r g i c a l
complication or aborted attempt at nerve-sparing. Para-
doxically, the patients with tumor (teratoma or carcinoma)
were less likely to have a surgical complication or a greater
chance at having nerve preservation. None of the variables
analyzed correlated with the presence of viable cancer.
The residual tumor size also correlated with complica-
tions. The mean size of retroperitoneal disease was
3.2 cm and 2.3 cm, with or without complications,
respectively (p = 0.03) (Figure 2c).
After PC-RPLND there were 7 (9.6%) patients with
disease recurrence, with only 2 (2.7%) within the
previously dissected field; one after a complete bilateral
dissection and another one after a right modified dissec-
tion. The first patient died due to disseminated neopla-
sia and the second one remains alive with active disease.
Among the 7 patients with recurrences (local or distant),
the retroperitoneal pathology was: teratoma (3 cases),
embryonal carcinoma (1 case), seminoma, (1 case), ade-
nocarcinoma (1 case) and fibrosis (1 case).
The estimated 5-year overall survival rate after
PC-RPLND was 91.2%. The estimated 5-year disease
free survival rate was 89.4% (Figure 2d). Median follow-
up was 47 months.
Discussion
Resection of residual tumor after complete serological
remission due to first and/or second line chemotherapy
Figure 2 A/B: correlation between PC-RPLND histology and nerve-sparing procedures (A) and surgical complications (B); C: correlation
between residual mass size and surgical complications; D: Five-year disease-free survival rate after PC-RPLND.
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lished staging and therapeutic procedure[9]. However, it
is important to continuously evaluate the rates of surgi-
cal complications, the presence of residual cancer post-
chemotherapy and clinical outcomes.
Defining the patients who actually would benefit the
most from this complex surgery is one of the most
important issues in the management of this disease. At
the moment, there are no reliable methods to select
patients with post-chemotherapy residual masses who
c o u l db eo b s e r v e dw i t h o u tr e section [10,11]. Imaging
methods are improving yet still fail to determine the
favorable group reliably[12]. In this study, we could not
identify any factor as a predictor for the presence of
viable cancer (risk, size, presence of teratoma, shrink-
ing). Perhaps molecular markers of the primary may
assist in the future.
PC-RPLND remains a challenging surgical procedure,
especially when large metastases become a fibrotic and
adherent to adjacent organs or vital structures[13]. In
tertiary centers the overall complications appear com-
parable to dissections in the primary setting, but there is
at e n d e n c yo fm o r es e v e r ec o m p l i c a t i o n si np o s t - c h e -
motherapy patients. Indeed, there is a significantly
longer operative time, bloodl o s s ,a n dt r a n s f u s i o nr a t e
with PC-RPLND[14,15]. Most common reported com-
plications are ileus and lymph leaks. More rarely, vascu-
lar and adjacent organ injuries can occur[16].
Nevertheless, these procedures can be done without
excessive risk as demonstrated by several others as well
as in this report[17].
The concept of reducing the extent of surgery when
fibrosis is detected intra-operatively is appealing. One
could consider partial resections or limited templates
when only fibrosis is suspected. Actually, this approach
was specifically addressed[6] and the authors could predict
presence of fibrosis in most cases using intra-operative
frozen sections. However, there remains concern regarding
this approach since intra-operative frozen section can mis-
classify disease in approximately 10-15% of cases.
Although intuitively, many believed that severe fibrosis
may be linked with complications, our analysis appears
to confirm this correlation. Furthermore, although
nerve-sparing procedures are feasible in the post-
chemotherapy setting[18], in our hands it appears to be
more difficult in the presence of fibrosis in residual
masses. These two findings represent the dilemma that
every surgeon faces when offering PC-RPLND. The
patients with higher rates of complications and less
likely to undergo nerve-sparing procedures, are exactly
those with minimum benefit from the procedure. A reli-
able predictive tool for viable cancer or teratoma in the
post-chemotherapy setting would be most welcome to
better select patients and reduce morbidity.
The rational to perform a lymph node dissection in
this group of patients is the fact that a significant num-
ber of patients will harbor viable teratoma or cancer
[2,15]. Although some authors suggest the possibility of
performing less extensive templates for selected residual
masses after chemotherapy[19], this approach has not
been accepted as standard of care and we could not
demonstrate a reliable pattern of dissemination to allow
safe modified dissections in this setting. The presence of
viable cancer post-chemotherapy varies from 4 to 20%
among tertiary centers. In our series we observed a
slightly higher rate of viable cancer than in the litera-
ture. Potential reasons for this observation may include:
suboptimal chemotherapy, delays in diagnosis, poor
adherence to treatment schedules and complex cases
poorly managed in community centres.
Several authors have been emphasizing the relation-
ship between surgical volume and outcomes[20]. Con-
sidering the complexity of this procedure and the
frequent need for multidisciplinary team assessment, we
join those who strongly recommend that the manage-
ment of patients with metastatic germ cell cancers be
restricted to specialized centers.
Finally, we report post-operative complications
according to the novel Clavien classification[7] and, as
in other areas of urologic surgery, this classification has
the potential to standardize the reporting of complica-
tions of RPLND. Additional studies using this classifica-
tion are required in order to validate it in this setting.
Conclusions
Post-chemotherapy retroperitoneal lymph node dissec-
tion is a relatively safe procedure. There remains a sig-
nificant proportion of patients with teratoma or viable
cancer after systemic treatment, justifying surgical resec-
tion. The presence of fibrosis and large residual masses
is associated with surgical complications and to a non-
nerve sparing procedure. There does not appear to be
reliable predictors of post-chemotherapy histology of
residual masses indicating the continued need for surgi-
cal resection in specialized centres.
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